Introduction

Knee osteoarthritis (OA) is a common and often painful condition that affects millions worldwide, limiting mobility and quality of life. Arthrosamid, a newer injectable treatment, is attracting growing interest as a less invasive alternative to surgery and long-term oral medications. This article takes a close look at how effective Arthrosamid really is by exploring the latest clinical findings, patient feedback, and comparisons with other treatments — helping you better understand if it could be the right option.

What is Arthrosamid and How Does It Work?

Arthrosamid is a type of polyacrylamide hydrogel (PAAG) injected directly into the knee joint. Unlike common gels like hyaluronic acid, Arthrosamid forms a thicker, cushioning scaffold that attaches to the synovial membrane — the soft lining inside the joint. In simple terms, it helps support and protect the joint tissues, reducing pain and improving function. Research explains that “it adheres to and bulks up the synovial membrane and acts as a scaffold to treat the synovium” (Cole et al., 2022). It’s generally suited to those with mild to moderate OA looking for a non-surgical way to ease symptoms.

What Does the Research Say?

Clinical studies show promising results for Arthrosamid. A comprehensive review from 2022 revealed “statistically significant data… at both 52 weeks and 13 months, indicating the efficacy of PAAG hydrogel at one year post injection” (Cole et al., 2022). Further studies continued to show benefits at two years. Importantly, the treatment appears to be safe: “Injection of PAAG hydrogel… has been shown to be safe with no long-lasting adverse events reported” (Cole et al., 2022). Supporting this, a 2025 laboratory study confirmed that “2.5 iPAAG had no statistically significant effects on cell survival, non-apoptotic and apoptotic cell death, or the neurite network area” (Walmod et al., 2025), highlighting the material’s safety on a cellular level.

How Does Arthrosamid Compare to Other Treatments?

When stacked against other common knee OA injections like corticosteroids and hyaluronic acid, Arthrosamid tends to hold its ground well. A 2025 study found that “iPAAG offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited” (Aykaç et al., 2025). Specifically, the study reported that “iPAAG outperformed Steroid at 6 months…but not HA… By 12 months, VAS [pain scores] returned to baseline in HA and Steroid, while iPAAG remained slightly improved” (Aykaç et al., 2025). Although it may not replace surgery for severe cases, Arthrosamid serves as a valuable non-surgical option that can delay or reduce the need for more invasive treatment.

Who Is Arthrosamid Best For? The Role of Imaging

Arthrosamid tends to work best for patients under 70 with mild to moderate knee OA and a healthy body weight. Before treatment, imaging tools like MRI or ultrasound help doctors assess the joint’s condition and identify who will benefit most. Those with advanced joint damage or deformities might not see as much improvement. This careful screening helps ensure the treatment is targeted and effective.

What Can You Expect After Treatment?

Many patients experience pain relief within a few weeks after their Arthrosamid injection, with improvements continuing for several months. One study noted “iPAAG showed the highest patient acceptable symptom state rates (72%, 54%, and 42% at 3, 6, and 12 months)” (Aykaç et al., 2025). Benefits often peak between six to twelve months and can last for up to three years. It’s important to understand that while Arthrosamid can greatly reduce symptoms, it isn’t a cure. Some might need repeat injections or other therapies down the line. Side effects are usually minor, such as occasional swelling or discomfort around the injection site. Many patients also report reduced reliance on painkillers and improved day-to-day mobility.

Conclusion

Arthrosamid is an effective, safe, and promising option for managing knee osteoarthritis, especially for those with mild to moderate symptoms seeking alternatives to surgery. The evidence shows it can provide lasting pain relief and improved joint function for up to three years, with high patient satisfaction and very low risks. While not a magic cure, it adds valuable choice to the range of available treatments. Proper patient selection and clear expectations mean Arthrosamid can play an important role in personalised OA care, helping many enjoy a more comfortable, active life.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(15). https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina‐Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430